CLOTBUST-ER Results Published in Lancet Neurology
The results of the CLOTBUST-ER trial, the first phase 3 trial to assess the safety and efficacy of sonothrombolysis, have been published in the April 2019 edition of Lancet Neurology. Though the trial did not meet its primary endpoint, the article and accompanying independent commentary offer a cogent review of the obstacles and shortcomings which may have impaired the CLOTBUST-ER trial, and highlights the continued promise of sonothrombolysis as a safe and effective option for acute ischemic stroke treatment. The publication also introduces the Cerevast Medical sponsored phase 3 TRUST study as an opportunity to incorporate the lessons learned from CLOTBUST-ER and unlock the potential of sonothrombolysis to advance the standard of care.
